Polyribosylribitol phosphate conjugated to tetanus toxoid (Polyribosylribitol phosphate conjugated to tetanus toxoid)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Vaccines, serums, phages and toxoids

Included in the formulation
АТХ:

J.07.A.G.   Vaccine for the prevention of infections caused by Haemophilus influenza B

Pharmacodynamics:

The vaccine induces the formation of antibodies to capsular polysaccharide Haemophilus influenzae type b.

Pharmacokinetics:

Not described.

Indications:

Prevention of purulent-septic diseases, which are caused by Haemophilus influenzae type b in children from 6 weeks to 5 years. The drug does not protect against diseases caused by other types Haemophilus influenza.

ICD-10

I.A30-A49.A49.2   Infection caused by Haemophilus influenza, unspecified

XXI.Z20-Z29.Z23.8   The need for immunization against another single bacterial disease

Contraindications:
  • Development of allergic reactions to the previous inoculation
  • Hypersensitivity
  • Acute infectious or non-infectious diseases, exacerbations of chronic diseases
Carefully:

No data.

Pregnancy and lactation:

The vaccine is not intended for adults.

Dosing and Administration:

Intramuscularly.

The course for children from 3 to 6 months: 3 injections of 0.5 ml with an interval of 1-1.5 months.

Course for children from 6 to 12 months: 2 injections of 0.5 ml at intervals of 1-1.5 months.

Course for children from 1 year to 5 years: a single injection of 0.5 ml.

Revaccination should be carried out once in 15-18 months in children who were vaccinated in the first year of life.

Intramuscularly or subcutaneously (patients with thrombocytopenia and other disorders of the blood coagulation system).

6 weeks -6 months: at the onset of vaccination up to 6 months of age, the course consists of 3 vaccinations at intervals of 1 month (2, 3, 4 or 3, 4, 5 months of life of the child) or 1.5 months (3, 4.5, 6 months) or 2 months between doses (2, 4 and 6 months). The vaccination scheme varies from country to country; in the Russian Federation, the initiation of vaccination against hemophilia b infection is envisaged from the age of 3 months. Revaccination is carried out once in the second year of life.

Vaccination is recommended to be carried out simultaneously with vaccination against poliomyelitis, pertussis, diphtheria and tetanus. In this regard, in accordance with the National Calendar of preventive vaccinations of the Russian Federation, scheme 3 is preferred; 4.5; 6 months with a booster at the age of 18 months.

6-12 months: at the onset of vaccination after 6 months of age, the course consists of 2 vaccinations at an interval of 1 month. Revaccination is carried out once in the second year of life.For example, vaccination at 6 and 7 months of the child's life and revaccination in 18 months of the child's life. The vaccine can be administered concomitantly with vaccination against poliomyelitis, pertussis, diphtheria, tetanus, measles, mumps and rubella.

1 year-5 years: at the onset of vaccination after 1 year, the vaccine is administered once.

The solvent should be examined before use for the presence of foreign particles and the physical properties of the solution. If there are foreign particles or change the appearance of the solution, it should not be used.

Immediately before use, the applied solvent is added to the vial of the vaccine at a rate of 0.5 ml per 1 dose. The vial is shaken well until the contents are completely dissolved. The lyophilisate usually dissolves within no more than 1 minute. The dissolved preparation is a clear, colorless liquid. If it looks different, and if there are foreign particles, the vaccine is not used. A new needle must be used to administer the drug. When using the vaccine in a multi-dose package, a new sterile syringe and needle should be used each time to take the drug.The drug should be removed from the bottle with strict adherence to aseptic rules to prevent contamination of the contents. The preparation from the opened vial should be used during the working day.

Side effects:

In the first 48 hours after administration, local painful reactions, hyperemia and others are possible. A subfebrile temperature reaction may also develop, loss of appetite, anxiety, nausea, diarrhea, unusual crying, which are usually mild and do not require therapy. Very rarely recorded allergic reactions (including anaphylactic shock). Side effects are usually not long and not intense. Otherwise, consult a doctor.

Overdose:

Not described.

Interaction:

In accordance with the rules existing in the Russian Federation, the drug can be administered simultaneously (on the same day) with other vaccines of the National calendar of preventive vaccinations, as well as inactivated vaccines of the vaccination calendar for epidemiological indications. In this case, drugs should be injected with different syringes into different parts of the body.

In individuals receiving immunosuppressive therapy, as with other vaccines,an adequate immune response may not be achieved.

Special instructions:

HIV infection is not a contraindication to the use of this vaccine.

In connection with the possibility of developing anaphylactic reaction in isolated cases, the vaccinated should be under medical supervision for 30 minutes, and the treatment rooms should be provided with anti-shock therapy.

Although the administration of the vaccine may cause a slight immune response to tetanus toxoid, administration of the vaccine can not replace vaccination against tetanus.

In persons receiving this vaccine, the capsular polysaccharide is released with urine, therefore, the determination of the antigen in the urine within 1-2 weeks after vaccination is of no diagnostic value in case of suspected infection caused by Haemophilus influenzae type b.

Instructions
Up